Acta Neuropathologica

, 116:1 | Cite as

A critical reappraisal of current staging of Lewy-related pathology in human brain

  • Kurt A. JellingerEmail author


Sporadic Parkinson disease (sPD) or brainstem-predominant type of Lewy body (LB) disease, and dementia with Lewy bodies (DLB), the two most frequent α-synucleinopathies, are progressive multisystem neurodegenerative disorders with widespread occurrence of α-synuclein (AS) deposits in the central, peripheral, and autonomic nervous system. For both LB-related disorders, staging/classification systems based on semiquantitative assessment of the distribution and progression pattern of Lewy-related/AS pathology are used that are considered to be linked to clinical dysfunctions. In PD, a six-stage system (Braak) has been suggested to indicate a predictable sequence of lesions with ascending progression from medullary and olfactory nuclei to the cortex, the first two presymptomatic stages being related to incidental LB disease, stages 3 and 4 with motor symptoms, and the last two (cortical) stages may be frequently associated with cognitive impairment. DLB, according to consensus pathologic guidelines, by semiquantitative scoring of AS pathology (LB density and distribution) in specific brain regions, is distinguished into three phenotypes (brainstem, transitional/limbic, and diffuse neocortical), also considering concomitant Alzheimer-related pathology. Retrospective clinico-pathologic studies, although largely confirming the staging system, particularly for younger onset PD with long duration, have shown that between 6.3 and 43% of the cases did not follow the proposed caudo-rostral progression pattern of AS pathology. There was sparing of medullary nuclei in 7–8.3% of clinically manifested PD cases with AS inclusions in midbrain and cortex corresponding to Braak stages 4 and 5, whereas mild parkinsonian symptoms were already observed in stages 2 and 3. There is considerable clinical and pathologic overlap between PD (with or without dementia) and DLB, corresponding to Braak LB stages 5 and 6, both frequently associated with variable Alzheimer-type pathology. Dementia often does not correlate with progressed stages of LB pathology, but may also be related to concomitant Alzheimer lesions or mixed pathologies. There is no relationship between Braak LB stage and the clinical severity of PD, and the predictive validity of this concept is doubtful, since large unselected, retrospective autopsy series in 30–55% of elderly subjects with widespread AS/Lewy-related pathology (Braak stages 5 and 6) reported no definite neuropsychiatric symptoms, suggesting considerable cerebral compensatory mechanisms. Applying the original criteria to large dementia samples, 49% of positive cases were not classifiable. Therefore, modified criteria for the categorization of Lewy-related pathology were proposed for patients with a history of dementia. The causes and molecular basis of the not infrequent deviations from the current staging schemes of AS pathology in PD and DLB, its relation to the onset of classical parkinsonian symptoms and for the lack of definite clinical deficits despite widespread AS pathology in the nervous system remain to be elucidated.


α-Synuclein deposits Lewy-related pathology Parkinson disease Dementia with Lewy bodies Neuropathologic staging systems Clinical relevance α-Synuclein and dementia 



The study was supported in part by the Society for the Support of Research in Experimental Neurology, Vienna, Austria. The author thanks G.H. Halliday for worthful comments and Mr. E. Mitter-Ferstl, PhD, for secretarial works.

Note added in proof

Among seven cases of autopsy proven DLB Kalaitzakis et al. [189] observed one case in which DMV and the whole spinal cord were devoid of AS pathology despite moderate AS deposition in rostral brainstem and cortex. The frequency, distribution, and severity of LBs in most neurodegenerative disorders (290 PSP, 13 Pick disease, 37 MSA, 49 FTLD, and 50 CBD) ranging from 8 to 12% was similar to that in 232 normal elderly controls, suggesting that in most cases this represents ILBD [188].


  1. 1.
    Aarsland D, Ballard CG, Halliday G (2004) Are Parkinson’s disease with dementia and dementia with Lewy bodies the same entity? J Geriatr Psychiatry Neurol 17:137–145PubMedGoogle Scholar
  2. 2.
    Abbott RD, Petrovitch H, White LR, Masaki KH, Tanner CM, Curb JD, Grandinetti A, Blanchette PL, Popper JS, Ross GW (2001) Frequency of bowel movements and the future risk of Parkinson’s disease. Neurology 57:456–462PubMedGoogle Scholar
  3. 3.
    Abbott RD, Ross GW, Petrovitch H, Tanner CM, Davis DG, Masaki KH, Launer LJ, Curb JD, White LR (2007) Bowel movement frequency in late-life and incidental Lewy bodies. Mov Disord 22:1581–1586PubMedGoogle Scholar
  4. 4.
    Aho L, Parkkinen L, Pirttila T, Alafuzoff I (2008) Systematic appraisal using immunohistochemistry of brain pathology in aged and demented subjects. Dement Geriatr Cogn Disord 25:423–432PubMedGoogle Scholar
  5. 5.
    Ala TA, Yang KH, Sung JH, Frey WH (2000) Inconsistency between severe substantia nigra degeneration with Lewy bodies and clinical parkinsonism in dementia patients: a cliniconeuropathological study. Acta Neuropathol 99:511–516PubMedGoogle Scholar
  6. 6.
    Alafuzoff I, Parkkinen L (2003) α-Synuclein in ageing and Alzheimer’s disease. In: Iqbal K, Winblad B (eds) Alzheimer’s disease and related disorders: research advances. Ana Aslan International Academy of Aging, Bucharest, pp 183–191Google Scholar
  7. 7.
    Alafuzoff I, Parkkinen L, Al-Sarraj S, Arzberger T, Bell J, Bodi I, Bogdanovic N, Budka H, Ferrer I, Gelpi E, Gentleman S, Giaccone G, Kamphorst W, King A, Korkolopoulou P, Kovacs GG, Larionov S, Meyronet D, Monoranu C, Morris J, Parchi P, Patsouris E, Roggendorf W, Seilhean D, Streichenberger N, Thal DR, Kretzschmar H (2008) Assessment of α-synuclein pathology: a study of the BrainNet Europe Consortium. J Neuropathol Exp Neurol 67:125–143PubMedGoogle Scholar
  8. 8.
    Alafuzoff I, Pikkarainen M, Arzberger T, Thal DR, Al-Sarraj S, Bell J, Bodi I, Budka H, Capetillo-Zarate E, Ferrer I, Gelpi E, Gentleman S, Giaccone G, Kavantzas N, King A, Korkolopoulou P, Kovacs GG, Meyronet D, Monoranu C, Parchi P, Patsouris E, Roggendorf W, Stadelmann C, Streichenberger N, Tagliavini F, Kretzschmar H (2008) Inter-laboratory comparison of neuropathological assessments of β-amyloid protein: a study of the BrainNet Europe consortium. Acta Neuropathol 115:533–546PubMedGoogle Scholar
  9. 9.
    Amino T, Orimo S, Itoh Y, Takahashi A, Uchihara T, Mizusawa H (2005) Profound cardiac sympathetic denervation occurs in Parkinson disease. Brain Pathol 15:29–34PubMedGoogle Scholar
  10. 10.
    Apaydin H, Ahlskog JE, Parisi JE, Boeve BF, Dickson DW (2002) Parkinson disease neuropathology: later-developing dementia and loss of the levodopa response. Arch Neurol 59:102–112PubMedGoogle Scholar
  11. 11.
    Attems J, Quass M, Jellinger KA (2007) Tau and α-synuclein brainstem pathology in Alzheimer disease: relation with extrapyramidal signs. Acta Neuropathol 113:53–62PubMedGoogle Scholar
  12. 12.
    Attems J, Jellinger KA (2008) The dorsal motor nucleus of the vagus is not an obligatory trigger site of Parkinson’s disease. Neuropathol Appl Neurobiol (in press). doi: 10.1111/j.1365-2990.2008.00937.x
  13. 13.
    Beach TG, Adler CH, Sue LI, Peirce JB, Bachalakuri J, Dalsing-Hernandez JE, Lue LF, Caviness JN, Connor DJ, Sabbagh MN, Walker DG (2008) Reduced striatal tyrosine hydroxylase in incidental Lewy body disease. Acta Neuropathol 115:445–451PubMedGoogle Scholar
  14. 14.
    Berger B, Gaspar P, Verney C (1991) Dopaminergic innervation of the cerebral cortex: unexpected differences between rodents and primates. Trends Neurosci 14:21–27PubMedGoogle Scholar
  15. 15.
    Bernheimer H, Birkmayer W, Hornykiewicz O, Jellinger K, Seitelberger F (1973) Brain dopamine and the syndromes of Parkinson and Huntington. Clinical, morphological and neurochemical correlations. J Neurol Sci 20:415–455PubMedGoogle Scholar
  16. 16.
    Bloch A, Probst A, Bissig H, Adams H, Tolnay M (2006) α-Synuclein pathology of the spinal and peripheral autonomic nervous system in neurologically unimpaired elderly subjects. Neuropathol Appl Neurobiol 32:284–295PubMedGoogle Scholar
  17. 17.
    Boeve BF, Dickson DW, Olson EJ, Shepard JW, Silber MH, Ferman TJ, Ahlskog JE, Benarroch EE (2007) Insights into REM sleep behavior disorder pathophysiology in brainstem-predominant Lewy body disease. Sleep Med 8:60–64PubMedGoogle Scholar
  18. 18.
    Braak H, Braak E, Yilmazer D, de Vos RA, Jansen EN, Bohl J, Jellinger K (1994) Amygdala pathology in Parkinson’s disease. Acta Neuropathol 88:493–500PubMedGoogle Scholar
  19. 19.
    Braak H, Braak E, Yilmazer D, de Vos RA, Jansen EN, Bohl J (1996) Pattern of brain destruction in Parkinson’s and Alzheimer’s diseases. J Neural Transm 103:455–490PubMedGoogle Scholar
  20. 20.
    Braak H, Del Tredici K, Rub U, de Vos RA, Jansen Steur EN, Braak E (2003) Staging of brain pathology related to sporadic Parkinson’s disease. Neurobiol Aging 24:197–211PubMedGoogle Scholar
  21. 21.
    Braak H, Ghebremedhin E, Rub U, Bratzke H, Del Tredici K (2004) Stages in the development of Parkinson’s disease-related pathology. Cell Tissue Res 318:121–134PubMedGoogle Scholar
  22. 22.
    Braak H, Rub U, Jansen Steur EN, Del Tredici K, de Vos RA (2005) Cognitive status correlates with neuropathologic stage in Parkinson disease. Neurology 64:1404–1410PubMedGoogle Scholar
  23. 23.
    Braak H, Bohl JR, Muller CM, Rub U, de Vos RA, Del Tredici K (2006) Stanley Fahn Lecture 2005: The staging procedure for the inclusion body pathology associated with sporadic Parkinson’s disease reconsidered. Mov Disord 21:2042–2051PubMedGoogle Scholar
  24. 24.
    Braak H, Muller CM, Rub U, Ackermann H, Bratzke H, de Vos RA, Del Tredici K (2006) Pathology associated with sporadic Parkinson’s disease—where does it end? J Neural Transm Suppl (70):89–97Google Scholar
  25. 25.
    Braak H, Sastre M, Bohl JR, de Vos RA, Del Tredici K (2007) Parkinson’s disease: lesions in dorsal horn layer I, involvement of parasympathetic and sympathetic pre- and postganglionic neurons. Acta Neuropathol 113:421–429PubMedGoogle Scholar
  26. 26.
    Braak H, Del Tredici K (2008) Nervous system pathology in sporadic Parkinson disease. Neurology 70:1916–1925PubMedGoogle Scholar
  27. 27.
    Burke RE, Dauer WT, Vonsattel JPG (2008) The Braak staging scheme for Parkinson’s disease: a reappraisal. Ann Neurol (submitted)Google Scholar
  28. 28.
    Cabello CR, Thune JJ, Pakkenberg H, Pakkenberg B (2002) Ageing of substantia nigra in humans: cell loss may be compensated by hypertrophy. Neuropathol Appl Neurobiol 28:283–291PubMedGoogle Scholar
  29. 29.
    Carvey PM, Punati A, Newman MB (2006) Progressive dopamine neuron loss in Parkinson’s disease: the multiple hit hypothesis. Cell Transplant 15:239–250PubMedGoogle Scholar
  30. 30.
    Caughey B, Lansbury PT (2003) Protofibrils, pores, fibrils, and neurodegeneration: separating the responsible protein aggregates from the innocent bystanders. Annu Rev Neurosci 26:267–298PubMedGoogle Scholar
  31. 31.
    Ciliax BJ, Drash GW, Staley JK, Haber S, Mobley CJ, Miller GW, Mufson EJ, Mash DC, Levey AI (1999) Immunocytochemical localization of the dopamine transporter in human brain. J Comp Neurol 409:38–56PubMedGoogle Scholar
  32. 32.
    Colosimo C, Hughes AJ, Kilford L, Lees AJ (2003) Lewy body cortical involvement may not always predict dementia in Parkinson’s disease. J Neurol Neurosurg Psychiatry 74:852–856PubMedGoogle Scholar
  33. 33.
    Dale GE, Probst A, Luthert P, Martin J, Anderton BH, Leigh PN (1992) Relationships between Lewy bodies and pale bodies in Parkinson’s disease. Acta Neuropathol 83:525–529PubMedGoogle Scholar
  34. 34.
    Damier P, Hirsch EC, Agid Y, Graybiel AM (1999) The substantia nigra of the human brain. I. Nigrosomes and the nigral matrix, a compartmental organization based on calbindin D(28K) immunohistochemistry. Brain 122(Pt 8):1421–1436PubMedGoogle Scholar
  35. 35.
    Davis DG, Schmitt FA, Wekstein DR, Markesbery WR (1999) Alzheimer neuropathologic alterations in aged cognitively normal subjects. J Neuropathol Exp Neurol 58:376–388PubMedGoogle Scholar
  36. 36.
    de Lau LM, Koudstaal PJ, Hofman A, Breteler MM (2006) Subjective complaints precede Parkinson disease: the rotterdam study. Arch Neurol 63:362–365PubMedGoogle Scholar
  37. 37.
    Del Tredici K, Rub U, De Vos RA, Bohl JR, Braak H (2002) Where does Parkinson disease pathology begin in the brain? J Neuropathol Exp Neurol 61:413–426PubMedGoogle Scholar
  38. 38.
    Del Tredici K, Braak H (2008) A not entirely benign procedure: progression of Parkinson’s disease. Acta Neuropathol 115:379–384PubMedGoogle Scholar
  39. 39.
    den Hartog Jager WA, Bethlem J (1960) The distribution of Lewy bodies in the central and autonomic nervous systems in idiopathic paralysis agitans. J Neurol Neurosurg Psychiatry 23:283–290PubMedGoogle Scholar
  40. 40.
    Deramecourt V, Bombois S, Maurage CA, Ghestem A, Drobecq H, Vanmechelen E, Lebert F, Pasquier F, Delacourte A (2006) Biochemical staging of synucleinopathy and amyloid deposition in dementia with Lewy bodies. J Neuropathol Exp Neurol 65:278–288PubMedGoogle Scholar
  41. 41.
    Dickson DW, Crystal HA, Mattiace LA, Masur DM, Blau AD, Davies P, Yen SH, Aronson MK (1992) Identification of normal and pathological aging in prospectively studied nondemented elderly humans. Neurobiol Aging 13:179–189PubMedGoogle Scholar
  42. 42.
    Dickson DW, Schmidt ML, Lee VM, Zhao ML, Yen SH, Trojanowski JQ (1994) Immunoreactivity profile of hippocampal CA2/3 neurites in diffuse Lewy body disease. Acta Neuropathol 87:269–276PubMedGoogle Scholar
  43. 43.
    Dickson DW, Fujishiro H, Delledonne A, Menke J, Ahmed Z, Klos KJ, Josephs KA, Frigerio R, Burnett M, Parisi JE, Ahlskog JE (2008) Evidence that incidental Lewy body disease is pre-symptomatic Parkinson’s disease. Acta Neuropathol 115:437–444PubMedGoogle Scholar
  44. 44.
    Duda JE, Giasson BI, Mabon ME, Lee VM, Trojanowski JQ (2002) Novel antibodies to synuclein show abundant striatal pathology in Lewy body diseases. Ann Neurol 52:205–210PubMedGoogle Scholar
  45. 45.
    Duda JE, Giasson BI, Mabon ME, Miller DC, Golbe LI, Lee VM, Trojanowski JQ (2002) Concurrence of α-synuclein and tau brain pathology in the Contursi kindred. Acta Neuropathol 104:7–11PubMedGoogle Scholar
  46. 46.
    Duda JE (2004) Pathology and neurotransmitter abnormalities of dementia with Lewy bodies. Dement Geriatr Cogn Disord 17(Suppl 1):3–14PubMedGoogle Scholar
  47. 47.
    Duka T, Rusnak M, Drolet RE, Duka V, Wersinger C, Goudreau JL, Sidhu A (2006) α-Synuclein induces hyperphosphorylation of tau in the MPTP model of parkinsonism. FASEB J 20:2302–2312PubMedGoogle Scholar
  48. 48.
    Farlow MR, Cummings J (2008) A modern hypothesis: The distinct pathologies of dementia associated with Parkinson’s disease versus Alzheimer’s disease. Dement Geriatr Cogn Disord 25:301–308PubMedGoogle Scholar
  49. 49.
    Fearnley JM, Lees AJ (1991) Ageing and Parkinson’s disease: substantia nigra regional selectivity. Brain 114(Pt 5):2283–2301PubMedGoogle Scholar
  50. 50.
    Fearnley JM, Lees AJ (1994) Pathology of Parkinson’s disease. In: Calne DB (ed) Neurodegenerative diseases. Saunders, Philadelphia, pp 545–554Google Scholar
  51. 51.
    Forno LS (1969) Concentric hyalin intraneuronal inclusions of Lewy type in the brains of elderly persons (50 incidental cases): relationship to parkinsonism. J Am Geriatr Soc 17:557–575PubMedGoogle Scholar
  52. 52.
    Frigerio R, Apaydin H, Klos KJ, Josephs KA, Parisi JE, Boeve B, Dickson DW, Ahlskog JE (2008) Substantia nigra Lewy bodies, neurofibrillary tangles, and aging (abstract). In: 60th Annual Meeting of the American Academy of Neurology, Chicago, April 12–19, 2008:P06.109.Google Scholar
  53. 53.
    Fujimi K, Sasaki K, Noda K, Wakisaka Y, Tanizaki Y, Matsui Y, Sekita A, Iida M, Kiyohara Y, Kanba S, Iwaki T (2008) Clinicopathological outline of dementia with lewy bodies applying the revised criteria: the Hisayama study. Brain Pathol 18:317–325PubMedGoogle Scholar
  54. 54.
    Fujishiro H, Tsuboi Y, Lin WL, Uchikado H, Dickson DW (2008) Co-localization of tau and α-synuclein in the olfactory bulb in Alzheimer’s disease with amygdala Lewy bodies. Acta Neuropathol (in press). doi: 10.1007/s00401-00008-00383-00401
  55. 55.
    Galpern WR, Lang AE (2006) Interface between tauopathies and synucleinopathies: a tale of two proteins. Ann Neurol 59:449–458PubMedGoogle Scholar
  56. 56.
    Galvin JE, Lee VM, Trojanowski JQ (2001) Synucleinopathies: clinical and pathological implications. Arch Neurol 58:186–190PubMedGoogle Scholar
  57. 57.
    Giasson BI, Forman MS, Higuchi M, Golbe LI, Graves CL, Kotzbauer PT, Trojanowski JQ, Lee VM (2003) Initiation and synergistic fibrillization of tau and α-synuclein. Science 300:636–640PubMedGoogle Scholar
  58. 58.
    Giasson BI, Covy JP, Bonini NM, Hurtig HI, Farrer MJ, Trojanowski JQ, Van Deerlin VM (2006) Biochemical and pathological characterization of Lrrk2. Ann Neurol 59:315–322PubMedGoogle Scholar
  59. 59.
    Gibb WR, Lees AJ (1988) The relevance of the Lewy body to the pathogenesis of idiopathic Parkinson’s disease. J Neurol Neurosurg Psychiatry 51:745–752PubMedGoogle Scholar
  60. 60.
    Gomez-Tortosa E, Newell K, Irizarry MC, Albert M, Growdon JH, Hyman BT (1999) Clinical and quantitative pathologic correlates of dementia with Lewy bodies. Neurology 53:1284–1291PubMedGoogle Scholar
  61. 61.
    Greffard S, Verny M, Bonnet AM, Beinis JY, Gallinari C, Meaume S, Piette F, Hauw JJ, Duyckaerts C (2006) Motor score of the Unified Parkinson Disease Rating Scale as a good predictor of Lewy body-associated neuronal loss in the substantia nigra. Arch Neurol 63:584–588PubMedGoogle Scholar
  62. 62.
    Greffard S, Verny M, Bonnet A, Seilhean D, Hauw J, Duyckaerts C (2008) The proportion of neurons containing Lewy bodies remains stable with time in the substantia nigra. A proposed model of neuronal death in relation to Lewy bodies (abstract). Clin Neuropathol 27:179Google Scholar
  63. 63.
    Greffard S, Verny M, Bonnet AM, Seilhean D, Hauw JJ, Duyckaerts C (2008) A stable proportion of Lewy body bearing neurons in the substantia nigra suggests a model in which the Lewy body causes neuronal death. Neurobiol Aging (in press)Google Scholar
  64. 64.
    Halliday G, Hely M, Reid W, Morris J (2008) The progression of pathology in longitudinally followed patients with Parkinson’s disease. Acta Neuropathol 115:409–415PubMedGoogle Scholar
  65. 65.
    Halliday GM, McRitchie DA, Cartwright H, Pamphlett R, Hely MA, Morris JGL (1996) Midbrain neuropathology in idiopathic Parkinson’s disease and diffuse Lewy body disease. J Clin Neurosci 3:52–60PubMedGoogle Scholar
  66. 66.
    Halliday GM, Del Tredici K, Braak H (2006) Critical appraisal of brain pathology staging related to presymptomatic and symptomatic cases of sporadic Parkinson’s disease. J Neural Transm Suppl (70):99–103Google Scholar
  67. 67.
    Hamilton RL (2000) Lewy bodies in Alzheimer’s disease: a neuropathological review of 145 cases using α-synuclein immunohistochemistry. Brain Pathol 10:378–384PubMedGoogle Scholar
  68. 68.
    Harding AJ, Halliday GM (2001) Cortical Lewy body pathology in the diagnosis of dementia. Acta Neuropathol 102:355–363PubMedGoogle Scholar
  69. 69.
    Harding AJ, Stimson E, Henderson JM, Halliday GM (2002) Clinical correlates of selective pathology in the amygdala of patients with Parkinson’s disease. Brain 125:2431–2445PubMedGoogle Scholar
  70. 70.
    Hawkes CH, Deeb J (2006) Predicting Parkinson’s disease: worthwhile but are we there yet? Pract Neurol 6:272–277CrossRefGoogle Scholar
  71. 71.
    Hawkes CH, Del Tredici K, Braak H (2007) Parkinson’s disease: a dual-hit hypothesis. Neuropathol Appl Neurobiol 33:599–614PubMedGoogle Scholar
  72. 72.
    Hely MA, Reid WG, Adena MA, Halliday GM, Morris JG (2008) The Sydney multicenter study of Parkinson’s disease: the inevitability of dementia at 20 years. Mov Disord 23:837–844PubMedGoogle Scholar
  73. 73.
    Higashi S, Iseki E, Yamamoto R, Minegishi M, Hino H, Fujisawa K, Togo T, Katsuse O, Uchikado H, Furukawa Y, Kosaka K, Arai H (2007) Concurrence of TDP-43, tau and α-synuclein pathology in brains of Alzheimer’s disease and dementia with Lewy bodies. Brain Res 1184:284–294PubMedGoogle Scholar
  74. 74.
    Hishikawa N, Hashizume Y, Yoshida M, Sobue G (2003) Clinical and neuropathological correlates of Lewy body disease. Acta Neuropathol 105:341–350PubMedGoogle Scholar
  75. 75.
    Hurtig HI, Trojanowski JQ, Galvin J, Ewbank D, Schmidt ML, Lee VM, Clark CM, Glosser G, Stern MB, Gollomp SM, Arnold SE (2000) α-Synuclein cortical Lewy bodies correlate with dementia in Parkinson’s disease. Neurology 54:1916–1921PubMedGoogle Scholar
  76. 76.
    Ince PG, Perry EK, Morris CM (1998) Dementia with Lewy bodies. A distinct non-Alzheimer dementia syndrome? Brain Pathol 8:299–324PubMedGoogle Scholar
  77. 77.
    Ince PG, Clark B, Holton J, Revesz T, Wharton SB (2008) Disorders of movement and system degenerations. In: Love S, Louis DN, Ellison DW (eds) Greenfield’s neuropathology, 8th edn. Hodder Arnold, London, pp 889–1030Google Scholar
  78. 78.
    Iseki E, Togo T, Suzuki K, Katsuse O, Marui W, de Silva R, Lees A, Yamamoto T, Kosaka K (2003) Dementia with Lewy bodies from the perspective of tauopathy. Acta Neuropathol 105:265–270PubMedGoogle Scholar
  79. 79.
    Ishizawa T, Mattila P, Davies P, Wang D, Dickson DW (2003) Colocalization of tau and α-synuclein epitopes in Lewy bodies. J Neuropathol Exp Neurol 62:389–397PubMedGoogle Scholar
  80. 80.
    Iwanaga K, Wakabayashi K, Yoshimoto M, Tomita I, Satoh H, Takashima H, Satoh A, Seto M, Tsujihata M, Takahashi H (1999) Lewy body-type degeneration in cardiac plexus in Parkinson’s and incidental Lewy body diseases. Neurology 52:1269–1271PubMedGoogle Scholar
  81. 81.
    Jellinger K (1987) Overview of morphological changes in Parkinson’s disease. Adv Neurol 45:1–18PubMedGoogle Scholar
  82. 82.
    Jellinger KA (2003) α-Synuclein pathology in Parkinson and Alzheimer disease brain: incidence and topographic distribution—a pilot study. Acta Neuropathol 106:191–201PubMedGoogle Scholar
  83. 83.
    Jellinger KA (2004) Lewy body-related α-synucleinopathy in the aged human brain. J Neural Transm 111:1219–1235PubMedGoogle Scholar
  84. 84.
    Jellinger KA, Attems J (2006) Does striatal pathology distinguish Parkinson disease with dementia and dementia with Lewy bodies? Acta Neuropathol 112:253–260PubMedGoogle Scholar
  85. 85.
    Jellinger KA (2007) Lewy body disorders. In: Youdim MBH, Riederer P, Mandel SA, Battistin L, Lajtha A (eds) Degenerative diseases of the nervous system. Springer Science, New York, pp 267–343Google Scholar
  86. 86.
    Jellinger KA (2007) Morphological substrates of Parkinsonism with and without dementia. A retrospective clinico-pathological study. J Neural Transm Suppl (72):91–104Google Scholar
  87. 87.
    Jellinger KA (2008) Striatal β-amyloid deposition in Parkinson disease with dementia. J Neuropathol Exp Neurol 67:484PubMedGoogle Scholar
  88. 88.
    Jellinger KA, Attems J (2008) Prevalence and impact of vascular and Alzheimer pathologies in Lewy body disease. Acta Neuropathol 115:427–436PubMedGoogle Scholar
  89. 89.
    Kalaitzakis ME, Graeber MB, Gentleman SM, Pearce RK (2008) The dorsal motor nucleus of the vagus is not an obligatory trigger site of Parkinson’s disease: a critical analysis of α-synuclein staging. Neuropathol Appl Neurobiol 34:284–295PubMedGoogle Scholar
  90. 90.
    Kalaitzakis ME, Graeber MB, Gentleman SM, Pearce RK (2008) Striatal β-amyloid deposition in Parkinson disease with dementia. J Neuropathol Exp Neurol 67:155–161PubMedGoogle Scholar
  91. 91.
    Kalaitzakis ME, Graeber MB, Gentleman SM, Pearce RK (2008c) Controversies over the staging of α-synuclein pathology in Parkinson’s disease. Acta Neuropathol, 30 April 2008 [Epub ahead of print]. doi: 10.1007/s00401-00008-00381-00403
  92. 92.
    Katsuse O, Iseki E, Marui W, Kosaka K (2003) Developmental stages of cortical Lewy bodies and their relation to axonal transport blockage in brains of patients with dementia with Lewy bodies. J Neurol Sci 211:29–35PubMedGoogle Scholar
  93. 93.
    Klos KJ, Ahlskog JE, Josephs KA, Apaydin H, Parisi JE, Boeve BF, DeLucia MW, Dickson DW (2006) α-Synuclein pathology in the spinal cords of neurologically asymptomatic aged individuals. Neurology 66:1100–1102PubMedGoogle Scholar
  94. 94.
    Klunk WE, Price JC, Mathis CA, Tsopelas ND, Lopresti BJ, Ziolko SK, Bi W, Hoge JA, Cohen AD, Ikonomovic MD, Saxton JA, Snitz BE, Pollen DA, Moonis M, Lippa CF, Swearer JM, Johnson KA, Rentz DM, Fischman AJ, Aizenstein HJ, DeKosky ST (2007) Amyloid deposition begins in the striatum of presenilin-1 mutation carriers from two unrelated pedigrees. J Neurosci 27:6174–6184PubMedGoogle Scholar
  95. 95.
    Knopman DS, Parisi JE, Salviati A, Floriach-Robert M, Boeve BF, Ivnik RJ, Smith GE, Dickson DW, Johnson KA, Petersen LE, McDonald WC, Braak H, Petersen RC (2003) Neuropathology of cognitively normal elderly. J Neuropathol Exp Neurol 62:1087–1095PubMedGoogle Scholar
  96. 96.
    Kosaka K, Mehraein P (1979) Dementia-Parkinsonism syndrome with numerous Lewy bodies and senile plaques in cerebral cortex. Arch Psychiatr Nervenkr 226:241–250PubMedGoogle Scholar
  97. 97.
    Kosaka K, Yoshimura M, Ikeda K, Budka H (1984) Diffuse type of Lewy body disease: progressive dementia with abundant cortical Lewy bodies and senile changes of varying degree - a new disease? Clin Neuropathol 3:185–192PubMedGoogle Scholar
  98. 98.
    Kosaka K (1995) Diffuse Lewy body disease. Rinsho Shinkeigaku 35:1455–1456PubMedGoogle Scholar
  99. 99.
    Kovacs GG, Milenkovic I, Preusser M, Budka H (2008) Nigral burden of α-synuclein correlates with the striatal dopamine deficit (abstract). Clin Neuropathol 27:177–178Google Scholar
  100. 100.
    Kovari E, Gold G, Herrmann FR, Canuto A, Hof PR, Bouras C, Giannakopoulos P (2003) Lewy body densities in the entorhinal and anterior cingulate cortex predict cognitive deficits in Parkinson’s disease. Acta Neuropathol 106:83–88PubMedGoogle Scholar
  101. 101.
    Kramer ML, Schulz-Schaeffer WJ (2007) Presynaptic α-synuclein aggregates, not Lewy bodies, cause neurodegeneration in dementia with Lewy bodies. J Neurosci 27:1405–1410PubMedGoogle Scholar
  102. 102.
    Kuusisto E, Parkkinen L, Alafuzoff I (2003) Morphogenesis of Lewy bodies: dissimilar incorporation of α-synuclein, ubiquitin, and p62. J Neuropathol Exp Neurol 62:1241–1253PubMedGoogle Scholar
  103. 103.
    Lang AE (2007) The progression of Parkinson disease: a hypothesis. Neurology 68:948–952PubMedGoogle Scholar
  104. 104.
    Lashley T, Holton JL, Gray E, Kirkham K, O’Sullivan SS, Hilbig A, Wood NW, Lees AJ, Revesz T (2008) Cortical α-synuclein load is associated with amyloid-β plaque burden in a subset of Parkinson’s disease patients. Acta Neuropathol 115:417–425PubMedGoogle Scholar
  105. 105.
    Lee VM, Giasson BI, Trojanowski JQ (2004) More than just two peas in a pod: common amyloidogenic properties of tau and α-synuclein in neurodegenerative diseases. Trends Neurosci 27:129–134PubMedGoogle Scholar
  106. 106.
    Leverenz JB, Hamilton R, Tsuang DW, Schantz A, Vavrek D, Larson EB, Kukull WA, Lopez O, Galasko D, Masliah E, Kaye J, Woltjer R, Clark C, Trojanowski JQ, Montine TJ (2008) Empiric refinement of the pathologic assessment of lewy-related pathology in the dementia patient. Brain Pathol 18:220–224PubMedGoogle Scholar
  107. 107.
    Li JY, Englund E, Holton JL, Soulet D, Hagell P, Lees AJ, Lashley T, Quinn NP, Rehncrona S, Bjorklund A, Widner H, Revesz T, Lindvall O, Brundin P (2008) Lewy bodies in grafted neurons in subjects with Parkinson’s disease suggest host-to-graft disease propagation. Nat Med 14(5):501–503PubMedGoogle Scholar
  108. 108.
    Linazasoro G (2007) Classical Parkinson disease versus Parkinson complex—reflections against staging and in favour of heterogeneity. Eur J Neurol 14:721–728PubMedGoogle Scholar
  109. 109.
    Lippa CF, Duda JE, Grossman M, Hurtig HI, Aarsland D, Boeve BF, Brooks DJ, Dickson DW, Dubois B, Emre M, Fahn S, Farmer JM, Galasko D, Galvin JE, Goetz CG, Growdon JH, Gwinn-Hardy KA, Hardy J, Heutink P, Iwatsubo T, Kosaka K, Lee VM, Leverenz JB, Masliah E, McKeith IG, Nussbaum RL, Olanow CW, Ravina BM, Singleton AB, Tanner CM, Trojanowski JQ, Wszolek ZK (2007) DLB and PDD boundary issues: diagnosis, treatment, molecular pathology, and biomarkers. Neurology 68:812–819PubMedGoogle Scholar
  110. 110.
    Litvan I, Halliday G, Hallett M, Goetz CG, Rocca W, Duyckaerts C, Ben-Shlomo Y, Dickson DW, Lang AE, Chesselet MF, Langston WJ, Di Monte DA, Gasser T, Hagg T, Hardy J, Jenner P, Melamed E, Myers RH, Parker D Jr, Price DL (2007) The etiopathogenesis of Parkinson disease and suggestions for future research. Part I. J Neuropathol Exp Neurol 66:251–257PubMedGoogle Scholar
  111. 111.
    Ma SY, Roytta M, Rinne JO, Collan Y, Rinne UK (1997) Correlation between neuromorphometry in the substantia nigra and clinical features in Parkinson’s disease using disector counts. J Neurol Sci 151:83–87PubMedGoogle Scholar
  112. 112.
    Ma SY, Roytta M, Collan Y, Rinne JO (1999) Unbiased morphometrical measurements show loss of pigmented nigral neurones with ageing. Neuropathol Appl Neurobiol 25:394–399PubMedGoogle Scholar
  113. 113.
    Ma SY, Ciliax BJ, Stebbins G, Jaffar S, Joyce JN, Cochran EJ, Kordower JH, Mash DC, Levey AI, Mufson EJ (1999) Dopamine transporter-immunoreactive neurons decrease with age in the human substantia nigra. J Comp Neurol 409:25–37PubMedGoogle Scholar
  114. 114.
    Mandal PK, Pettegrew JW, Masliah E, Hamilton RL, Mandal R (2006) Interaction between Aβ peptide and α synuclein: molecular mechanisms in overlapping pathology of Alzheimer’s and Parkinson’s in dementia with Lewy body disease. Neurochem Res 31:1153–1162PubMedGoogle Scholar
  115. 115.
    Marion MH, Qurashi M, Marshall G, Foster O (2008) Is REM sleep behaviour disorder (RBD) a risk factor of dementia in idiopathic Parkinson’s disease? J Neurol 255:192–196PubMedGoogle Scholar
  116. 116.
    Marui W, Iseki E, Nakai T, Miura S, Kato M, Ueda K, Kosaka K (2002) Progression and staging of Lewy pathology in brains from patients with dementia with Lewy bodies. J Neurol Sci 195:153–159PubMedGoogle Scholar
  117. 117.
    Marras C, Lang A (2008) Changing concepts in Parkinson disease: moving beyond the decade of the brain. Neurology 70:1996–2003PubMedGoogle Scholar
  118. 118.
    Mattila PM, Rinne JO, Helenius H, Dickson DW, Roytta M (2000) α-Synuclein-immunoreactive cortical Lewy bodies are associated with cognitive impairment in Parkinson’s disease. Acta Neuropathol 100:285–290PubMedGoogle Scholar
  119. 119.
    McKeith IG, Galasko D, Kosaka K, Perry EK, Dickson DW, Hansen LA, Salmon DP, Lowe J, Mirra SS, Byrne EJ, Lennox G, Quinn NP, Edwardson JA, Ince PG, Bergeron C, Burns A, Miller BL, Lovestone S, Collerton D, Jansen EN, Ballard C, de Vos RA, Wilcock GK, Jellinger KA, Perry RH (1996) Consensus guidelines for the clinical and pathologic diagnosis of dementia with Lewy bodies (DLB): report of the consortium on DLB international workshop. Neurology 47:1113–1124PubMedGoogle Scholar
  120. 120.
    McKeith IG, Dickson DW, Lowe J, Emre M, O’Brien JT, Feldman H, Cummings J, Duda JE, Lippa C, Perry EK, Aarsland D, Arai H, Ballard CG, Boeve B, Burn DJ, Costa D, Del Ser T, Dubois B, Galasko D, Gauthier S, Goetz CG, Gomez-Tortosa E, Halliday G, Hansen LA, Hardy J, Iwatsubo T, Kalaria RN, Kaufer D, Kenny RA, Korczyn A, Kosaka K, Lee VM, Lees A, Litvan I, Londos E, Lopez OL, Minoshima S, Mizuno Y, Molina JA, Mukaetova-Ladinska EB, Pasquier F, Perry RH, Schulz JB, Trojanowski JQ, Yamada M (2005) Diagnosis and management of dementia with Lewy bodies: third report of the DLB Consortium. Neurology 65:1863–1872PubMedGoogle Scholar
  121. 121.
    McRitchie DA, Cartwright HR, Halliday GM (1997) Specific A10 dopaminergic nuclei in the midbrain degenerate in Parkinson’s disease. Exp Neurol 144:202–213PubMedGoogle Scholar
  122. 122.
    Meredith GE, Sonsalla PK, Chesselet MF (2008) Animal models of Parkinson’s disease progression. Acta Neuropathol 115:385–398PubMedGoogle Scholar
  123. 123.
    Mirra SS, Heyman A, McKeel D, Sumi SM, Crain BJ, Brownlee LM, Vogel FS, Hughes JP, van Belle G, Berg L (1991) The Consortium to Establish a Registry for Alzheimer’s Disease (CERAD). Part II. Standardization of the neuropathologic assessment of Alzheimer’s disease. Neurology 41:479–486PubMedGoogle Scholar
  124. 124.
    Mitsui J, Saito Y, Momose T, Shimizu J, Arai N, Shibahara J, Ugawa Y, Kanazawa I, Tsuji S, Murayama S (2006) Pathology of the sympathetic nervous system corresponding to the decreased cardiac uptake in 123I-metaiodobenzylguanidine (MIBG) scintigraphy in a patient with Parkinson disease. J Neurol Sci 243:101–104PubMedGoogle Scholar
  125. 125.
    Moore DJ, West AB, Dawson VL, Dawson TM (2005) Molecular pathophysiology of Parkinson’s disease. Annu Rev Neurosci 28:57–87PubMedGoogle Scholar
  126. 126.
    Mori F, Nishie M, Kakita A, Yoshimoto M, Takahashi H, Wakabayashi K (2006) Relationship among α-synuclein accumulation, dopamine synthesis, and neurodegeneration in Parkinson disease substantia nigra. J Neuropathol Exp Neurol 65:808–815PubMedGoogle Scholar
  127. 127.
    Mori F, Tanji K, Zhang H, Kakita A, Takahashi H, Wakabayashi K (2008) α-Synuclein pathology in the neostriatum in Parkinson’s disease. Acta Neuropathol 115:453–459PubMedGoogle Scholar
  128. 128.
    Mori H (2005) Pathological substrate of dementia in Parkinson’s disease—its relation to DLB and DLBD. Parkinsonism Relat Disord 11(Suppl 1):S41–45PubMedGoogle Scholar
  129. 129.
    Morris JC, Storandt M, McKeel DW Jr, Rubin EH, Price JL, Grant EA, Berg L (1996) Cerebral amyloid deposition and diffuse plaques in “normal” aging: evidence for presymptomatic and very mild Alzheimer’s disease. Neurology 46:707–719PubMedGoogle Scholar
  130. 130.
    Mosimann UP, McKeith IG (2003) Dementia with Lewy bodies and Parkinson’s disease dementia—two synucleinopathies. Adv Clin Neurosci Rehabil 3:8–16Google Scholar
  131. 131.
    Müller CM, de Vos RA, Maurage CA, Thal DR, Tolnay M, Braak H (2005) Staging of sporadic Parkinson disease-related α-synuclein pathology: inter- and intra-rater reliability. J Neuropathol Exp Neurol 64:623–628PubMedGoogle Scholar
  132. 132.
    Murayama S (2004) Systemic pathology of Lewy-related Parkinson changes in aging. The experience of Tokyo Metropolitan Brain Bank for Aging Research. In: Yamamoto M (ed) Parkinson’s disease: advances in pathology and autonomic nervous system. Chugai Igaku, Tokyo, pp 34–45Google Scholar
  133. 133.
    Nurmi E, Ruottinen HM, Bergman J, Haaparanta M, Solin O, Sonninen P, Rinne JO (2001) Rate of progression in Parkinson’s disease: a 6-[18F]fluoro-l-dopa PET study. Mov Disord 16:608–615PubMedGoogle Scholar
  134. 134.
    Orimo S, Amino T, Itoh Y, Takahashi A, Kojo T, Uchihara T, Tsuchiya K, Mori F, Wakabayashi K, Takahashi H (2005) Cardiac sympathetic denervation precedes neuronal loss in the sympathetic ganglia in Lewy body disease. Acta Neuropathol 109:583–588PubMedGoogle Scholar
  135. 135.
    Outeiro TF, McLean PJ, Hyman BT (2007) Protein aggregation disorders. In: Gilman S (ed) Neurobiology of disease. Elsevier Academic Press, Amsterdam, pp 111–123Google Scholar
  136. 136.
    Oyanagi K, Wakabayashi K, Ohama E, Takeda S, Horikawa Y, Morita T, Ikuta F (1990) Lewy bodies in the lower sacral parasympathetic neurons of a patient with Parkinson’s disease. Acta Neuropathol 80:558–559PubMedGoogle Scholar
  137. 137.
    Pan T, Kondo S, Le W, Jankovic J (2008) The role of autophagy-lysosome pathway in neurodegeneration associated with Parkinson’s disease. Brain (in press). doi: 10.1093/brain/awm1318
  138. 138.
    Parkkinen L, Soininen H, Laakso M, Alafuzoff I (2001) α-Synuclein pathology is highly dependent on the case selection. Neuropathol Appl Neurobiol 27:314–325PubMedGoogle Scholar
  139. 139.
    Parkkinen L, Soininen H, Alafuzoff I (2003) Regional distribution of α-synuclein pathology in unimpaired aging and Alzheimer disease. J Neuropathol Exp Neurol 62:363–367PubMedGoogle Scholar
  140. 140.
    Parkkinen L, Kauppinen T, Pirttila T, Autere JM, Alafuzoff I (2005) α-Synuclein pathology does not predict extrapyramidal symptoms or dementia. Ann Neurol 57:82–91PubMedGoogle Scholar
  141. 141.
    Parkkinen L, Pirttila T, Tervahauta M, Alafuzoff I (2005) Widespread and abundant α-synuclein pathology in a neurologically unimpaired subject. Neuropathology 25:304–314PubMedGoogle Scholar
  142. 142.
    Parkkinen L, Pirttila T, Alafuzoff I (2008) Applicability of current staging/categorization of α-synuclein pathology and their clinical relevance. Acta Neuropathol 115:399–407PubMedGoogle Scholar
  143. 143.
    Piao YS, Mori F, Hayashi S, Tanji K, Yoshimoto M, Kakita A, Wakabayashi K, Takahashi H (2003) α-Synuclein pathology affecting Bergmann glia of the cerebellum in patients with α-synucleinopathies. Acta Neuropathol 105:403–409PubMedGoogle Scholar
  144. 144.
    Piccini P, Brooks DJ (2006) New developments of brain imaging for Parkinson’s disease and related disorders. Mov Disord 21:2035–2041PubMedGoogle Scholar
  145. 145.
    Pletnikova O, West N, Lee MK, Rudow GL, Skolasky RL, Dawson TM, Marsh L, Troncoso JC (2005) Aβ deposition is associated with enhanced cortical α-synuclein lesions in Lewy body diseases. Neurobiol Aging 26:1183–1192PubMedGoogle Scholar
  146. 146.
    Price JL, Morris JC (1999) Tangles and plaques in nondemented aging and “preclinical” Alzheimer’s disease. Ann Neurol 45:358–368PubMedGoogle Scholar
  147. 147.
    Price JL, Ko AI, Wade MJ, Tsou SK, McKeel DW, Morris JC (2001) Neuron number in the entorhinal cortex and CA1 in preclinical Alzheimer disease. Arch Neurol 58:1395–1402PubMedGoogle Scholar
  148. 148.
    Probst A, Bloch A, Tolnay M (2008) New insights into the pathology of Parkinson’s disease: does the peripheral autonomic system become central? Eur J Neurol 15(Suppl):1–4PubMedGoogle Scholar
  149. 149.
    Przedborski S (2006) Etiology and pathogenesis of Parkinson’s disease. In: Jankovic JJ, Tolosa E (eds) Parkinson’s disease and movement disorders, 5th edn. Lippincott Williams & Wilkins, Philadelphia, pp 77–92Google Scholar
  150. 150.
    Przuntek H, Muller T, Riederer P (2004) Diagnostic staging of Parkinson’s disease: conceptual aspects. J Neural Transm 111:201–216PubMedGoogle Scholar
  151. 151.
    Richard IH, Papka M, Rubio A, Kurlan R (2002) Parkinson’s disease and dementia with Lewy bodies: one disease or two? Mov Disord 17:1161–1165PubMedGoogle Scholar
  152. 152.
    Riederer P, Gerlach M, Muller T, Reichmann H (2007) Relating mode of action to clinical practice: dopaminergic agents in Parkinson’s disease. Parkinsonism Relat Disord 13:466–479PubMedGoogle Scholar
  153. 153.
    Rudow G, O’Brien R, Savonenko AV, Resnick SM, Zonderman AB, Pletnikova O, Marsh L, Dawson TM, Crain BJ, West MJ, Troncoso JC (2008) Morphometry of the human substantia nigra in ageing and Parkinson’s disease. Acta Neuropathol 115:461–470PubMedGoogle Scholar
  154. 154.
    Saha AR, Hill J, Utton MA, Asuni AA, Ackerley S, Grierson AJ, Miller CC, Davies AM, Buchman VL, Anderton BH, Hanger DP (2004) Parkinson’s disease α-synuclein mutations exhibit defective axonal transport in cultured neurons. J Cell Sci 117:1017–1024PubMedGoogle Scholar
  155. 155.
    Saito Y, Ruberu NN, Sawabe M, Arai T, Kazama H, Hosoi T, Yamanouchi H, Murayama S (2004) Lewy body-related α-synucleinopathy in aging. J Neuropathol Exp Neurol 63:742–749PubMedGoogle Scholar
  156. 156.
    Sanchez-Gonzalez MA, Garcia-Cabezas MA, Rico B, Cavada C (2005) The primate thalamus is a key target for brain dopamine. J Neurosci 25:6076–6083PubMedGoogle Scholar
  157. 157.
    Schapira AH (2006) Etiology of Parkinson’s disease. Neurology 66:S10–23PubMedGoogle Scholar
  158. 158.
    Schlossmacher MG (2007) α-Synuclein and synucleinopathies. In: Growdon JH, Rossor MN (eds) The Dementias 2. Blue Books of Neurology. Butterworth-Heinemann Oxford, pp 184–213Google Scholar
  159. 159.
    Shao CY, Crary JF, Rao C, Sacktor TC, Mirra SS (2006) Atypical protein kinase C in neurodegenerative disease II: PKCiota/lambda in tauopathies and α-synucleinopathies. J Neuropathol Exp Neurol 65:327–335PubMedGoogle Scholar
  160. 160.
    Shih MC, Franco de Andrade LA, Amaro E Jr, Felicio AC, Ferraz HB, Wagner J, Hoexter MQ, Lin LF, Fu YK, Mari JJ, Tufik S, Bressan RA (2007) Higher nigrostriatal dopamine neuron loss in early than late onset Parkinson’s disease? A [99mTc]-TRODAT-1 SPECT study. Mov Disord 22:863–866PubMedGoogle Scholar
  161. 161.
    Sossi V, de la Fuente-Fernandez R, Schulzer M, Troiano AR, Ruth TJ, Stoessl AJ (2007) Dopamine transporter relation to dopamine turnover in Parkinson’s disease: a positron emission tomography study. Ann Neurol 62:468–474PubMedGoogle Scholar
  162. 162.
    Soto C, Estrada LD (2008) Protein misfolding and neurodegeneration. Arch Neurol 65:184–189PubMedGoogle Scholar
  163. 163.
    Stiasny-Kolster K, Doerr Y, Moller JC, Hoffken H, Behr TM, Oertel WH, Mayer G (2005) Combination of ‘idiopathic’ REM sleep behaviour disorder and olfactory dysfunction as possible indicator for α-synucleinopathy demonstrated by dopamine transporter FP-CIT-SPECT. Brain 128:126–137PubMedGoogle Scholar
  164. 164.
    Sulzer D (2007) Multiple hit hypotheses for dopamine neuron loss in Parkinson’s disease. Trends Neurosci 30:244–250PubMedGoogle Scholar
  165. 165.
    Takeda S, Yamazaki K, Miyakawa T, Arai H (1993) Parkinson’s disease with involvement of the parasympathetic ganglia. Acta Neuropathol 86:397–398PubMedGoogle Scholar
  166. 166.
    Tanaka M, Kim YM, Lee G, Junn E, Iwatsubo T, Mouradian MM (2004) Aggresomes formed by α-synuclein and synphilin–1 are cytoprotective. J Biol Chem 279:4625–4631PubMedGoogle Scholar
  167. 167.
    Tofaris GK, Spillantini MG (2005) α-Synuclein dysfunction in Lewy body diseases. Mov Disord 20(Suppl 12):S37–S44PubMedGoogle Scholar
  168. 168.
    Tsuboi Y, Dickson DW (2005) Dementia with Lewy bodies and Parkinson’s disease with dementia: are they different? Parkinsonism Relat Disord 11(Suppl 1):S47–S51PubMedGoogle Scholar
  169. 169.
    Uchihara T, Paulus W (2008) Research into neurodegenerative disease: an entangled web of mice and men. Acta Neuropathol 115:1–4PubMedGoogle Scholar
  170. 170.
    Uchikado H, Lin WL, DeLucia MW, Dickson DW (2006) Alzheimer disease with amygdala Lewy bodies: a distinct form of α-synucleinopathy. J Neuropathol Exp Neurol 65:685–697PubMedGoogle Scholar
  171. 171.
    Uitti RJ, Calne DB, Dickson DW, Wszolek ZK (2004) Is the neuropathological ‘gold standard’ diagnosis dead? Implications of clinicopathological findings in an autosomal dominant neurodegenerative disorder. Parkinsonism Relat Disord 10:461–463PubMedGoogle Scholar
  172. 172.
    Volles MJ, Lansbury PT Jr (2003) Zeroing in on the pathogenic form of α-synuclein and its mechanism of neurotoxicity in Parkinson’s disease. Biochemistry 42:7871–7878PubMedGoogle Scholar
  173. 173.
    Wakabayashi K, Takahashi H, Takeda S, Ohama E, Ikuta F (1988) Parkinson’s disease: the presence of Lewy bodies in Auerbach’s and Meissner’s plexuses. Acta Neuropathol 76:217–221PubMedGoogle Scholar
  174. 174.
    Wakabayashi K, Takahashi H, Ohama E, Ikuta F (1990) Parkinson’s disease: an immunohistochemical study of Lewy body-containing neurons in the enteric nervous system. Acta Neuropathol 79:581–583PubMedGoogle Scholar
  175. 175.
    Wakabayashi K, Takahashi H, Obata K, Ikuta F (1992) Immunocytochemical localization of synaptic vesicle-specific protein in Lewy body-containing neurons in Parkinson’s disease. Neurosci Lett 138:237–240PubMedGoogle Scholar
  176. 176.
    Wakabayashi K, Takahashi H, Ohama E, Takeda S, Ikuta F (1993) Lewy bodies in the visceral autonomic nervous system in Parkinson’s disease. Adv Neurol 60:609–612PubMedGoogle Scholar
  177. 177.
    Wakabayashi K, Takahashi H (1997) Neuropathology of autonomic nervous system in Parkinson’s disease. Eur Neurol 38(Suppl 2):2–7PubMedGoogle Scholar
  178. 178.
    Wakabayashi K, Toyoshima Y, Awamori K, Anezaki T, Yoshimoto M, Tsuji S, Takahashi H (1999) Restricted occurrence of Lewy bodies in the dorsal vagal nucleus in a patient with late-onset parkinsonism. J Neurol Sci 165:188–191PubMedGoogle Scholar
  179. 179.
    Wakabayashi K, Mori F, Takahashi H (2006) Progression patterns of neuronal loss and Lewy body pathology in the substantia nigra in Parkinson’s disease. Parkinsonism Relat Disord 12(1):92–98Google Scholar
  180. 180.
    Wakabayashi K, Tanji K, Mori F, Takahashi H (2007) The Lewy body in Parkinson’s disease: molecules implicated in the formation and degradation of α-synuclein aggregates. Neuropathology 27:494–506PubMedGoogle Scholar
  181. 181.
    Wakisaka Y, Furuta A, Tanizaki Y, Kiyohara Y, Iida M, Iwaki T (2003) Age-associated prevalence and risk factors of Lewy body pathology in a general population: the Hisayama study. Acta Neuropathol 106:374–382PubMedGoogle Scholar
  182. 182.
    Weisman D, Cho M, Taylor C, Adame A, Thal LJ, Hansen LA (2007) In dementia with Lewy bodies, Braak stage determines phenotype, not Lewy body distribution. Neurology 69:356–359PubMedGoogle Scholar
  183. 183.
    Wolters E, Braak H (2006) Parkinson’s disease: premotor clinico-pathological correlations. J Neural Transm Suppl (70):309–319Google Scholar
  184. 184.
    Yamamoto R, Iseki E, Marui W, Togo T, Katsuse O, Kato M, Isojima D, Akatsu H, Kosaka K, Arai H (2005) Non-uniformity in the regional pattern of Lewy pathology in brains of dementia with Lewy bodies. Neuropathology 25:188–194PubMedGoogle Scholar
  185. 185.
    Yokota O, Tsuchiya K, Uchihara T, Ujike H, Terada S, Takahashi M, Kimura Y, Ishizu H, Akiyama H, Kuroda S (2007) Lewy body variant of Alzheimer’s disease or cerebral type lewy body disease? Two autopsy cases of presenile onset with minimal involvement of the brainstem. Neuropathology 27:21–35PubMedGoogle Scholar
  186. 186.
    Zaccai J, Brayne C, McKeith I, Matthews F, Ince PG (2008) Patterns and stages of α-synucleinopathy: relevance in a population-based cohort. Neurology 70:1042–1048PubMedGoogle Scholar
  187. 187.
    Zarow C, Lyness SA, Mortimer JA, Chui HC (2003) Neuronal loss is greater in the locus coeruleus than nucleus basalis and substantia nigra in Alzheimer and Parkinson diseases. Arch Neurol 60:337–341PubMedGoogle Scholar
  188. 188.
    Fujishiro H, Ahn TB, Frigerio R, Uchikado H, Klos KJ, Josephs KA, DelleDonne A, Parisi JE, Ahlskog JE, Dickson DW (2008) Incidental Lewy bodies in various neurodegenerative disorders (abstr.). Mov Disord 23 (Suppl.1):S30Google Scholar
  189. 189.
    Kalaitzakis ME, Roncaroli F, Pearce RK, Gentleman S (2008) Non-steroetypical distribution of α-synuclein in the spinal cord and brain of a patient with dementia with Lewy bodies (DLB) (abstr.). Mov Disord 23 (Suppl.1):S247Google Scholar

Copyright information

© Springer-Verlag 2008

Authors and Affiliations

  1. 1.Institute of Clinical NeurobiologyViennaAustria

Personalised recommendations